Shockwave Medical - SWAV Stock Forecast, Price & News

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Shockwave Medical in the last year. There are currently 1 sell rating, 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SWAV shares.
View SWAV analyst ratings or view top-rated stocks.

9 Wall Street research analysts have issued 1 year price targets for Shockwave Medical's shares. Their SWAV share price forecasts range from $165.00 to $310.00. On average, they anticipate the company's share price to reach $247.40 in the next year. This suggests a possible upside of 14.8% from the stock's current price.
View analysts price targets for SWAV or view top-rated stocks among Wall Street analysts.

Shockwave Medical's stock was trading at $205.61 at the start of the year. Since then, SWAV stock has increased by 4.8% and is now trading at $215.56.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023.
View our SWAV earnings forecast.

Shockwave Medical, Inc. (NASDAQ:SWAV) released its quarterly earnings results on Thursday, February, 16th. The company reported $3.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.99 by $2.72. The company earned $144 million during the quarter, compared to the consensus estimate of $143.04 million. Shockwave Medical had a net margin of 44.10% and a trailing twelve-month return on equity of 59.99%. The company's revenue for the quarter was up 71.0% on a year-over-year basis. During the same period in the prior year, the firm earned $0.34 earnings per share.

ETFs with the largest weight of Shockwave Medical (NASDAQ:SWAV) stock in their portfolio include Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD), Neuberger Berman Disrupters ETF (NBDS), Invesco S&P MidCap 400 Pure Growth ETF (RFG), Invesco S&P MidCap Quality ETF (XMHQ), SPDR S&P Health Care Equipment ETF (XHE), First Trust US Equity Opportunities ETF (FPX), Goldman Sachs Future Health Care Equity ETF (GDOC) and SoFi Next 500 ETF (SFYX).

Shockwave Medical issued an update on its FY 2023 earnings guidance on Wednesday, March, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $660.00 million-$680.00 million, compared to the consensus revenue estimate of $658.58 million.

8 employees have rated Shockwave Medical Chief Executive Officer Doug Godshall on Glassdoor.com. Doug Godshall has an approval rating of 89% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Shockwave Medical investors own include NVIDIA (NVDA), Walt Disney (DIS), Block (SQ), Trade Desk (TTD), Salesforce (CRM), Roku (ROKU), PayPal (PYPL), DexCom (DXCM), Alibaba Group (BABA) and Okta (OKTA).

(SWAV) raised $75 million in an IPO on Thursday, March 7th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Morgan Stanley and BofA Merrill Lynch served as the underwriters for the IPO and Wells Fargo Securities and Canaccord Genuity were co-managers.

Shockwave Medical trades on the NASDAQ under the ticker symbol "SWAV."

Shockwave Medical's stock is owned by a variety of institutional and retail investors. Top institutional investors include Price T Rowe Associates Inc. MD (2.80%), JPMorgan Chase & Co. (2.23%), Macquarie Group Ltd. (2.09%), Gilder Gagnon Howe & Co. LLC (1.95%), Geode Capital Management LLC (1.86%) and Artisan Partners Limited Partnership (1.85%). Insiders that own company stock include Antoine Papiernik, Colin Cahill, Dan Puckett, Douglas Evan Godshall, Frank T Watkins, Frank T Watkins, Isaac Zacharias, Kurt F Gallo, Laura Francis, Maria Sainz, Sofinnova Capital Vii Fcpr and Trinh Phung.
View institutional ownership trends.

Shares of SWAV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SWAV stock can currently be purchased for approximately $215.56.

Shockwave Medical (NASDAQ:SWAV) has a market capitalization of $7.87 billion and generates $489.73 million in revenue each year. The company earns $216 million in net income (profit) each year or $5.70 on an earnings per share basis.

The company employs 1,001 workers across the globe.

Shockwave Medical's mailing address is 5403 Betsy Ross Drive, Santa Clara CA, 95054. The official website for the company is www.shockwavemedical.com. The company can be reached via phone at (877) 775-4846 or via email at investors@shockwavemedical.com.